Understand the source comparison
Research Design Considerations: ACE-031 vs Follistatin Selection
For myostatin-selective research (studying GDF-8-specific biology, myostatin dose-response, genetic myostatin-null comparison contexts), neither ACE-031 nor FST-288 is the ideal tool — both capture multiple ligands. Anti-myostatin selective antibodies (e.g., L
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- For myostatin-selective research (studying GDF-8-specific biology, myostatin dose-response, genetic myostatin-null comparison contexts), neither ACE-031 nor FST-288 is the ideal tool — both capture multiple ligands. Anti-myostatin selective antibodies (e.g., LY2495655, stamulumab) or myostatin propeptide provide greater selectivity for pure myostatin research. When broad myostatin-superfamily pathway blockade is the research intent (closer to maximal muscle growth phenotype), both ACE-031 and FST-288 are appropriate.
- The primary selection criterion for ACE-031 vs FST-288 is the research question regarding activin A. If activin A is a co-variable of interest (cachexia, aged muscle high-activin A environment, post-surgical muscle wasting), FST-288 provides superior activin A capture for its affinity advantage. If BMP9/10 vascular biology must be preserved as unperturbed controls (pulmonary hypertension research context, vascular biology experiments), FST-288 is preferred as it does not capture BMP9/10. If Fc-mediated effector functions or longer half-life (ACE-031 Fc-mediated t1/2 ~14 days vs FST t1/2 ~2–4 hours in circulation) are required for once-weekly or biweekly dosing schedules without osmotic pump delivery, ACE-031’s Fc fusion is advantageous. For local intramuscular delivery via AAV or recombinant protein, FST-288 or FST-315 can be delivered at high local concentrations without systemic activin A capture concerns.